Food-Effect Bioavailability Study of AQ-13, a Candidate Antimalarial

• Status: Completed
• Trial end date: 2006-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to test the safety of a 2100 mg dose of AQ-13, a new candidate antimalarial active against drug-resistant P. falciparum infection, and to determine the effect of a standard fatty meal on the absorption of the drug from the gut and its blood levels.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Tulane University Health Sciences Center
• Collaborator: Centers for Disease Control and Prevention
• Treatments: Antimalarials

Criteria

Inclusion Criteria:

• Healthy volunteers 21-45 years of age taking no chronic medications other than birth-control pills

Exclusion Criteria:

• Pregnancy,

• Breast-feeding,

• Chronic disease